Brian Schroer, MD

Wright joins Schroer for a discussion on updates in pediatric eosinophilic esophagitis at AAAAI 2026.

New data reveal who misses oral food challenges despite scheduling, spotlighting race and insurance gaps—and the barriers clinics can fix.

Brian Schroer, MD, highlights recent data exploring the origins of EoE inflammation and the efficacy and limitations of recent biologic treatments.

Host Brian Schroer, MD, interviews Sathya Areti, MD, about her case study presented at ACAAI 2025.

Host Brian Schroer, MD, interviews Melissa Ptak, DO, about her research presented at ACAAI 2025.

Part 4 highlights how expanding epinephrine delivery options can reduce barriers, support earlier administration, and improve real-world anaphylaxis outcomes.

In this segment, experts emphasize the importance of giving an infant experiencing anaphylaxis epinephrine at whatever dose may be available rather than delaying treatment.

In the second part of the special report, panelists delink epinephrine use from mandatory emergency department visits.

In the opening segment of this special report, panelists discuss updated anaphylaxis guidelines and early management priorities.

In the final part of this 5-part series, panelists discuss new allergy treatments such as Xolair, early immunotherapy, and their broader impact.

In part 4 of this 5-part series, panelists discuss gaps in pediatric food allergy care, stressing better diagnosis, education, and management.

In part 3 of this 5-part series, panelists discuss the recent Neffy approval, oral immunotherapy, and Xolair’s role in allergy management.

In part 2 of this 5-part series, panelists discuss confusion in food allergy diagnosis and the need for better medical education.

In part 1 of this 5-part series, panelists discuss early allergen introduction, oral immunotherapy, and Xolair for food allergy.